FY2025 · ended Dec 31, 2025 · Revenue $68,379, +144.3% YoY · Filed Mar 31, 2026
Vivos Inc. (RDGL) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $68,379 and a net loss of $3.1 million. Free cash flow was -$2.2 million. As of Jun 30, 2026 it held $2.3 million in cash and investments and $103,153 in total debt.
Revenue (TTM)
$99,099
+91.5% vs year-ago TTM
Net income (TTM)
$-3.60M
-8.2% vs year-ago TTM
Operating cash flow (TTM)
$-2.17M
-6.4% vs year-ago TTM
Free cash flow
$-2.16M
EPS (TTM)
$-0.01
-1.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
482.69M
+6.5% vs prior year
Net cash
$2.23M
as of Jun 30, 2026
Operating margin
-2852.5%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- RDGL (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Richland, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1449349
- Former names
- ADVANCED MEDICAL ISOTOPE Corp (until Dec 18, 2017)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $68,379 | $27,995 | $19,500 | $36,499 | $14,887 |
| Operating income | -$3.2M | -$2.6M | -$2.8M | -$2.5M | -$2.5M |
| Net income | -$3.1M | -$2.9M | -$2.9M | -$2.5M | -$2.5M |
| Diluted EPS | -$0.01 | -$0.01 | -$0.01 | — | — |
| Operating cash flow | -$2.1M | -$1.7M | -$1.3M | -$1.1M | -$963,819 |
| Free cash flow | -$2.2M | — | — | — | — |
| Total assets | $1.9M | $2.2M | $1.6M | $1.7M | $1.6M |
| Total liabilities | $206,743 | $86,209 | $245,004 | $81,692 | $166,915 |
| Stockholders' equity | $1.7M | $2.1M | $1.4M | $1.7M | $1.5M |
| Cash and investments | $1.6M | $2.2M | $1.6M | — | — |
| Total debt | $114,271 | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Bylaw or fiscal year change
|
Oct 8, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Oct 5, 2026 | Sep 28, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
All 496 Vivos Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.